SCHEMBL2148609

SCHEMBL2148609

NCCCNCCOP(=O)(O)S

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.49
DRD3 P35462 1/20 0.49
CA12 O43570 3/20 0.43
CA2 P00918 3/20 0.43
CA4 P22748 3/20 0.43
CA6 P23280 3/20 0.43
CA5A P35218 3/20 0.43
CA7 P43166 3/20 0.43
CA9 Q16790 3/20 0.43
CA14 Q9ULX7 3/20 0.43
CA5B Q9Y2D0 3/20 0.43
CASP2 P42575 2/20 0.43
F13A1 P00488 2/20 0.43
CYP1A2 P05177 2/20 0.43
ALOX15 P16050 2/20 0.43
THPO P40225 2/20 0.43
MEN1 O00255 1/20 0.43
CYP2C19 P33261 1/20 0.43
RECQL P46063 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL6575430 0.98 BLM (0.47) BLMDRD3CA12CA2CA4
Water SCHEMBL5319737 0.98 BLM (0.47) BLMDRD3CA12CA2CA4
Water SCHEMBL8576389 0.98 BLM (0.47) BLMDRD3CA12CA2CA4
SCHEMBL9172734 0.85 DRD3 (0.52) BLMDRD3CA12CA2CA4
SCHEMBL29021959 0.82 DRD3 (0.46) BLMDRD3CA12CA2CA4
SCHEMBL2148646 0.80 SAT1 (0.62) CA12CA2CA9CYP1A2MEN1
SCHEMBL4388966 0.80 SAT1 (0.45) CA12CA2CA9CA1SAT1
SCHEMBL8722018 0.77 CA12 (0.46) BLMDRD3CA12CA2CA4
SCHEMBL14782501 0.76 ANPEP (0.44) BLMDRD3CA12CA2CA4
SCHEMBL5247222 0.76 LPAR3 (0.42) BLMCA12CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200360406-A1 SELECTIVE ACCRETION OF CYTOPROTECTANT IN RADIATION-SENSITIVE TISSUES AND USES THEREOF WILLIAM MARSH RICE UNIVERSITY (US) 2020-11-19 US claimed
US-6573253-B2 Protecting against or treating toxicities associated with ionizing radiation by subcutaneously administering compounds such as S-3-(3-methylaminopropylamino)propyl dihydrogen phosphorothioate prior to exposure MEDIMMUNE ONCOLOGY INC. 2003-06-03 US claimed
US-5906984-A Methods of using aminothiols to promote hematopoietic progenitor cell growth ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 1999-05-25 US claimed
US-5804571-A ADMINISTERING AN S-OMEGA(OMEGA-AMINOALKYLAMINO)ALKYL DIHYDROGEN PHOSPHOROTHIOATE U.S. BIOSCIENCE (US) 1998-09-08 US claimed
WO-2024211590-A1 PHARMACEUTICALLY ACTIVE COMPOSITIONS AND USES THEREOF XERIENT PHARMA LTD. (IL) 2024-10-10 WO disclosed
US-11478489-B2 Selective accretion of cytoprotectant in radiation-sensitive tissues and uses thereof WILLIAM MARSH RICE UNIVERSITY (US) 2022-10-25 US disclosed
US-20200360406-A1 SELECTIVE ACCRETION OF CYTOPROTECTANT IN RADIATION-SENSITIVE TISSUES AND USES THEREOF WILLIAM MARSH RICE UNIVERSITY (US) 2020-11-19 US disclosed
EP-3713534-A1 SELECTIVE ACCRETION OF CYTOPROTECTANT IN RADIATION-SENSITIVE TISSUES AND USES THEREOF William Marsh Rice University (US) 2020-09-30 EP disclosed
WO-2019103983-A1 SELECTIVE ACCRETION OF CYTOPROTECTANT IN RADIATION-SENSITIVE TISSUES AND USES THEREOF WILLIAM MARSH RICE UNIVERSITY (US) 2019-05-31 WO disclosed
EP-2714715-B1 PHARMACEUTICAL COMPOSITIONS SEECURE TAIWAN CO LTD (TW) 2019-01-23 EP disclosed
US-8648042-B2 Pharmaceutical compositions TAIWAN HOPAX CHEMS. MFG. CO., LTD. (TW) 2014-02-11 US disclosed
US-20130090312-A1 METHODS OF USE RELATED TO XEROSTOMIA MEDIMMUNE LLC (US) 2013-04-11 US disclosed
EP-0409845-A4 METHOD FOR PROTECTION FROM CHEMOTHERAPEUTIC SIDE EFFECTS 1991-07-03 EP disclosed
EP-0409845-A4 METHOD FOR PROTECTION FROM CHEMOTHERAPEUTIC SIDE EFFECTS 1991-07-03 EP disclosed
US-5017693-A Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound NEORX CORPORATION (US) 1991-05-21 US disclosed
EP-0409845-A1 METHOD FOR PROTECTION FROM CHEMOTHERAPEUTIC SIDE EFFECTS U.S. BIOSCIENCE (US) 1991-01-30 EP disclosed
EP-0409845-A1 METHOD FOR PROTECTION FROM CHEMOTHERAPEUTIC SIDE EFFECTS U.S. BIOSCIENCE (US) 1991-01-30 EP disclosed
WO-1990014007-A1 METHOD FOR PROTECTION FROM AZT SIDE EFFECTS AND TOXICITY U.S. BIOSCIENCE (US) 1990-11-29 WO disclosed
WO-1989007942-A1 METHOD FOR PROTECTION FROM CHEMOTHERAPEUTIC SIDE EFFECTS U.S. BIOSCIENCE (US) 1989-09-08 WO disclosed
WO-1989007942-A1 METHOD FOR PROTECTION FROM CHEMOTHERAPEUTIC SIDE EFFECTS U.S. BIOSCIENCE (US) 1989-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11478489-B2 Selective accretion of cytoprotectant in radiation-sensitive tissues and uses thereof HSPE1, TXNRD2, TXN2 BLM 789/4885DRD3 4644/4885CA12 2244/4885
US-20200360406-A1 SELECTIVE ACCRETION OF CYTOPROTECTANT IN RADIATION-SENSITIVE TISSUES AND USES THEREOF HSPE1, TXNRD2, TXN2 BLM 789/4885DRD3 4644/4885CA12 2244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.